Liposomal Bupivicaine (Exparel) for Pain Control During Care of Rib Fractures

Trial Profile

Liposomal Bupivicaine (Exparel) for Pain Control During Care of Rib Fractures

Withdrawn prior to enrolment
Phase of Trial: Phase IV

Latest Information Update: 24 Jan 2017

At a glance

  • Drugs Bupivacaine (Primary)
  • Indications Pain
  • Focus Therapeutic Use
  • Most Recent Events

    • 17 Jan 2017 Planned End Date changed from 1 Apr 2016 to 1 Jan 2017.
    • 17 Jan 2017 Planned primary completion date changed from 1 Apr 2016 to 1 Jan 2017.
    • 07 Jun 2015 Status changed from not yet recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top